Berlin – While working at SMP, Martin Schaper advised 1717 Life Science Ventures on the sale of its stake in drug developer PENTIXAPHARM to Eckert & Ziegler Strahlen- und Medizintechnik AG. In the course of the transaction, Eckert & Ziegler acquired a direct majority stake in PENTIXAPHARM, a joint venture between Scintomics GmbH and 1717 Life Science Ventures GmbH.
The team has already advised on the establishment of the joint venture in 2019.
With a solid history of building successful radiopharmaceutical startups, the 1717 team has personal experience in all key functions of an early-stage radiopharmaceutical development company. PENTIXAPHARM is developing a radiopharmaceutical combination product for lymphoma and a number of related tumors. Together with an internal transfer, Eckert & Ziegler says it will directly hold around 83% of the shares in the Würzburg-based company after the closing. The management of PENTIXAPHARM, which holds the remaining 17% of PENTIXAPHARM shares, also received put options on the remaining shares as part of the share sale. Further information can be found here.
Advisors 1717 Life Science Ventures GmbH:
Dr. Martin Schaper, Partner
About us
YPOG is a law firm specialized in tax and business law, active in the core fields of Funds, Tax, Banking + Finance, and Transactions. The team at YPOG represents a broad client base, which ranges from emerging technology companies and family-run SMEs to large corporations, as well as private equity, and venture capital funds. YPOG is one of the leading advisors for venture capital, private equity, and fund structuring in Germany. The firm and its partners have been recognized nationally and internationally by JUVE, Best Lawyers, Legal 500, Focus, Chambers and Partners as well as Leaders League. Today, YPOG has more than 150 experienced attorneys, tax advisors and tax specialists and a notary, in four offices, located in Berlin, Hamburg, Cologne, and Munich.
